The Next Generation Sequencing market is categorized by product (software and services) and by applications. By product it is segmented into whole targeted re-sequencing, genome sequencing, exome sequencing, de novo sequencing, RNA-Seq, ChIP-Seq and Methyl-Seq. By application it is sub segmented into diagnostics, drug discovery, biomarker discovery, personalized medicine, and animal & agriculture research. On the basis of geography, the European Next Generation sequencing Market is analysed under various regions namely, Spain, Germany, UK, France and Italy.
The Europe NGS Market which was worth USD 1.16 billion by the end of 2018 is expected to reach USD 2.35 billion by 2023 at a CAGR of 15.17%.
Increased usage of personalized medicine, development in NGS bioinformatics and pre sequencing solutions and cloud computing, growth in population, increasing prevalence of infectious diseases and chronic diseases such as cancer are few factors driving the market growth. In addition, anticipated decrease in the prices of genome sequencing due to development of rapid, high capacity whole genome sequencers by key players is anticipate to show an an optimistic effect on market penetration rates over the few years. However, the storage and management of data generated by sequencing and its interpretation, high reliability on grants & funding from the government and fall in capital expenditure from academic institutions are some of the key challenges for Europe next generation sequencing market.
Illumina Incorporated, Thermo Fischer Scientific, Life Sciences (Roche),Pacific Biosciences, Life Technologies Corp. (Thermo Fischer Scientific), Macrogen Inc.,Partek Inc., Genomatix Software GmbH, Perkin Elmer inc.,GATC Biotech Ag, Agilent Technologies Inc., Biomatters Ltd., CLC Bio (Qiagen), BGI (Beijing Genomics Institute), Oxford Nanopore Technologies Ltd.,Pacific Biosciences, DNASTAR Inc., Knome Inc., Illumina Inc., and Qiagen N.V.
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2.1 Introduction
2.2 Analysis Design
2.3 Research Phases
2.3.1 Secondary Research
2.3.2 Primary Research
2.3.3 Econometric Modelling
2.3.4 Expert Validation
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5.1 By Product
5.1.1 Software
5.1.2 Services
5.2 By Technology
5.2.1 Whole Targeted Re-Sequencing
5.2.2 Genome Sequencing
5.2.3 De Novo Sequencing
5.2.4 Exome Sequencing
5.2.5 RNA-Seq
5.2.6 ChIP-Seq
5.2.7 Methyl-Seq
5.3 By Application
5.3.1 Diagnostics
5.3.2 Drug Discovery
5.3.3 Biomarker Discovery
5.3.4 Personalized Medicine
5.3.5 Agriculture and Animals Research
6.1 Introduction
6.2 U.K
6.3 Spain
6.4 Germany
6.5 Italy
6.6 France
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.1 Macrogen Inc.
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Thermo Fischer Scientific
8.3 Life Sciences (Roche)
8.4 Pacific Biosciences
8.5 Life Technologies Corp.
8.6 Partek Inc.
8.7 Genomatix Software GmbH
8.8 Perkin Elmer Inc.
8.9 GATC Biotech Ag
8.10 Agilent Technologies Inc.
8.11 Biomatters Ltd.
8.12 CLC Bio (Qiagen)
8.13 Pacific Biosciences
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
